Completed

Evaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Abicipar pegol

Drug
Who is being recruted

Eye Diseases+1

+ Macular Degeneration

+ Retinal Degeneration

Over 50 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: May 2018
See protocol details

Summary

Principal SponsorAllergan
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 25, 2018

Actual date on which the first participant was enrolled.

The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).

Official TitleEvaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
NCT03539549
Principal SponsorAllergan
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

124 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Eye DiseasesMacular DegenerationRetinal DegenerationRetinal Diseases

Criteria

3 inclusion criteria required to participate
Male or female participants, 50 years of age or older at the time of informed consent
Best Corrected Visual Acuity (BCVA) ≤ 78 and ≥ 24 letters (20/32 to 20/320 Snellen equivalents, respectively) at Screening and at Baseline (Day 1, prior to treatment) visits in the study eye
BCVA of 34 letters (Snellen equivalent 20/200) or better at Baseline (Day 1, prior to treatment) in the non-study eye
3 exclusion criteria prevent from participating
Cataract or refractive surgery within 3 months prior to baseline (study eye)
Active periocular, ocular, or intraocular infection at baseline (Day 1) (either eye)
Previous or concurrent macular laser treatment (study eye)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 37 locations

Suspended

Barnet Dulaney Perkins Eye Center

Phoenix, United StatesOpen Barnet Dulaney Perkins Eye Center in Google Maps
Suspended

Retina Associates Southwest, PC

Tucson, United States
Suspended

Win Retina

Arcadia, United States
Suspended

N. California Retina Vitreous Associates Medical Group, INC.

Mountain View, United States
Completed37 Study Centers